{
    "clinical_study": {
        "@rank": "41713", 
        "arm_group": {
            "arm_group_label": "Study Group", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive a single booster dose of Tdap vaccine (ADACEL\u00ae) on Day 0."
        }, 
        "brief_summary": {
            "textblock": "This study is designed to assess the immunogenicity and safety of tetanus toxoid, reduced\n      diphtheria toxoid and acellular pertussis vaccine (ADACEL\u00ae, Tdap vaccine) as a booster dose\n      in adolescents in Japan.\n\n      Primary Objective:\n\n        -  To assess the immunogenicity of Tdap (SP306) when administered as a single dose in\n           Japanese adolescents\n\n      Secondary Objective:\n\n        -  To assess the safety of Tdap vaccine when administered as a single dose in Japanese\n           adolescents."
        }, 
        "brief_title": "Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL\u00ae) as a Booster in Adolescents", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Participants received a single booster dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis vaccine (Tdap vaccine; ADACEL\u00ae) on Day 0.", 
                        "title": "Study Group"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "43"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "43"
                                            }
                                        }, 
                                        "sub_title": "<=18 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": "Between 18 and 65 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": ">=65 years"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Age", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "0.5", 
                                            "@value": "11.4"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "Years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "23"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "20"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "43"
                                        }
                                    }, 
                                    "sub_title": "Japan"
                                }
                            }, 
                            "param": "Number", 
                            "title": "Region of Enrollment", 
                            "units": "Participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "Seroprotection was defined as the percentage of participants with antibody concentration of \u22650.1 IU/mL, post-vaccination.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received a single booster dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis vaccine (Tdap vaccine; ADACEL\u00ae) on Day 0.", 
                                "title": "Study Group"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "43"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "100"
                                                    }
                                                }, 
                                                "sub_title": "Diphtheria"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "100"
                                                    }
                                                }, 
                                                "sub_title": "Tetanus"
                                            }
                                        ]
                                    }, 
                                    "description": "Seroprotection was defined as the percentage of participants with antibody concentration of \u22650.1 IU/mL, post-vaccination.", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Following Vaccination With ADACEL\u00ae", 
                                    "units": "Percentage of Participants"
                                }
                            ]
                        }, 
                        "population": "Seroprotection to diphtheria and tetanus antigens were determined in the Immunology Analysis Set", 
                        "safety_issue": "No", 
                        "time_frame": "Day 28 post-vaccination", 
                        "title": "Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Following Vaccination With ADACEL\u00ae", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Diphtheria booster response was defined as a \u2265 4-fold rise in pre- to post-vaccination antitoxin concentration in a subject with a pre-vaccination antitoxin concentration \u2264 2.56 IU/mL; or a \u2265 2-fold rise in a subject with a pre-vaccination antitoxin concentration > 2.56 IU/mL.\nTetanus booster response was defined as a \u2265 4-fold rise in pre- to post- vaccination antitoxin concentration in a subject with a pre-vaccination antitoxin concentration \u2264 2.7 IU/mL; or a \u2265 2-fold rise in a subject with a pre-vaccination antitoxin concentration > 2.7 IU/mL.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received a single booster dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis vaccine (Tdap vaccine; ADACEL\u00ae) on Day 0.", 
                                "title": "Study Group"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "43"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "98"
                                                    }
                                                }, 
                                                "sub_title": "Diphtheria"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "100"
                                                    }
                                                }, 
                                                "sub_title": "Tetanus"
                                            }
                                        ]
                                    }, 
                                    "description": "Diphtheria booster response was defined as a \u2265 4-fold rise in pre- to post-vaccination antitoxin concentration in a subject with a pre-vaccination antitoxin concentration \u2264 2.56 IU/mL; or a \u2265 2-fold rise in a subject with a pre-vaccination antitoxin concentration > 2.56 IU/mL.\nTetanus booster response was defined as a \u2265 4-fold rise in pre- to post- vaccination antitoxin concentration in a subject with a pre-vaccination antitoxin concentration \u2264 2.7 IU/mL; or a \u2265 2-fold rise in a subject with a pre-vaccination antitoxin concentration > 2.7 IU/mL.", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants With Booster Response to Diphtheria and Tetanus Antigens Following Vaccination With ADACEL\u00ae", 
                                    "units": "Percentage of Participants"
                                }
                            ]
                        }, 
                        "population": "Booster response to diphtheria and tetanus antigens were determined in the Immunology Analysis Set", 
                        "safety_issue": "No", 
                        "time_frame": "Day 28 post-vaccination", 
                        "title": "Percentage of Participants With Booster Response to Diphtheria and Tetanus Antigens Following Vaccination With ADACEL\u00ae", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Booster responses were defined as: Pre-vaccination antibody concentrations less than the lower limit of quantitation (LLOQ) and a post-vaccination levels \u2265 4x LLOQ; or Pre-vaccination antibody concentrations \u2265 LLOQ but < 4x LLOQ, and a 4-fold rise (i.e., post-/pre-vaccination \u2265 4), or Pre-vaccination antibody concentrations \u2265 4x LLOQ and a 2-fold rise (i.e., post-/pre-vaccination \u2265 2)", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received a single booster dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis vaccine (Tdap vaccine; ADACEL\u00ae) on Day 0.", 
                                "title": "Study Group"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "43"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "63"
                                                    }
                                                }, 
                                                "sub_title": "Pertussis toxoid"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "88"
                                                    }
                                                }, 
                                                "sub_title": "Filamentous hemagglutinin"
                                            }
                                        ]
                                    }, 
                                    "description": "Booster responses were defined as: Pre-vaccination antibody concentrations less than the lower limit of quantitation (LLOQ) and a post-vaccination levels \u2265 4x LLOQ; or Pre-vaccination antibody concentrations \u2265 LLOQ but < 4x LLOQ, and a 4-fold rise (i.e., post-/pre-vaccination \u2265 4), or Pre-vaccination antibody concentrations \u2265 4x LLOQ and a 2-fold rise (i.e., post-/pre-vaccination \u2265 2)", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants With Booster Response to Pertussis Antigens, Pertussis Toxoid and Filamentous Hemagglutinin Following Vaccination With ADACEL\u00ae", 
                                    "units": "Percentage of Participants"
                                }
                            ]
                        }, 
                        "population": "Booster response to pertussis antigens were determined in the Immunology Analysis Set", 
                        "safety_issue": "No", 
                        "time_frame": "Day 28 post-vaccination", 
                        "title": "Percentage of Participants With Booster Response to Pertussis Antigens, Pertussis Toxoid and Filamentous Hemagglutinin Following Vaccination With ADACEL\u00ae", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Seroprotection was defined as the percentage of participants with antibody concentration of \u22650.1 IU/mL.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received a single booster dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis vaccine (Tdap vaccine; ADACEL\u00ae) on Day 0.", 
                                "title": "Study Group"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "43"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "63"
                                                    }
                                                }, 
                                                "sub_title": "Diphtheria"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "91"
                                                    }
                                                }, 
                                                "sub_title": "Tetanus"
                                            }
                                        ]
                                    }, 
                                    "description": "Seroprotection was defined as the percentage of participants with antibody concentration of \u22650.1 IU/mL.", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Pre-vaccination With ADACEL\u00ae", 
                                    "units": "Percentage of Participants"
                                }
                            ]
                        }, 
                        "population": "Pre-vaccination seroprotection to diphtheria and tetanus antigens were determined in the Immunology Analysis Set", 
                        "safety_issue": "No", 
                        "time_frame": "Day 0 pre-vaccination", 
                        "title": "Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Pre-vaccination With ADACEL\u00ae", 
                        "type": "Other Pre-specified"
                    }, 
                    {
                        "description": "Seroprotection was defined as the percentage of participants with antibody concentration of \u22650.01 IU/mL.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received a single booster dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis vaccine (Tdap vaccine; ADACEL\u00ae) on Day 0.", 
                                "title": "Study Group"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "43"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "100"
                                                    }
                                                }, 
                                                "sub_title": "Diphtheria (Pre-vaccination)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "100"
                                                    }
                                                }, 
                                                "sub_title": "Diphtheria (Post-vaccination)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "100"
                                                    }
                                                }, 
                                                "sub_title": "Tetanus (Pre-vaccination)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "100"
                                                    }
                                                }, 
                                                "sub_title": "Tetanus (Post-vaccination)"
                                            }
                                        ]
                                    }, 
                                    "description": "Seroprotection was defined as the percentage of participants with antibody concentration of \u22650.01 IU/mL.", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Pre-vaccination and Post-vaccination With ADACEL\u00ae", 
                                    "units": "Percentage of Participants"
                                }
                            ]
                        }, 
                        "population": "Pre- and post-vaccination seroprotection to diphtheria and tetanus antigens were determined in the Immunology Analysis Set.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 0 (pre-vaccination) and day 28 post-vaccination", 
                        "title": "Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Pre-vaccination and Post-vaccination With ADACEL\u00ae", 
                        "type": "Other Pre-specified"
                    }, 
                    {
                        "description": "Seroprotection was defined as the percentage of participants with antibody concentration of \u22651.0 IU/mL.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received a single booster dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis vaccine (Tdap vaccine; ADACEL\u00ae) on Day 0.", 
                                "title": "Study Group"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "43"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "12"
                                                    }
                                                }, 
                                                "sub_title": "Diphtheria (Pre-vaccination)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "100"
                                                    }
                                                }, 
                                                "sub_title": "Diphtheria (Post-vaccination)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "30"
                                                    }
                                                }, 
                                                "sub_title": "Tetanus (Pre-vaccination)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "100"
                                                    }
                                                }, 
                                                "sub_title": "Tetanus (Post-vaccination)"
                                            }
                                        ]
                                    }, 
                                    "description": "Seroprotection was defined as the percentage of participants with antibody concentration of \u22651.0 IU/mL.", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Pre-vaccination and Post-vaccination With ADACEL\u00ae", 
                                    "units": "Percentage of Participants"
                                }
                            ]
                        }, 
                        "population": "Pre- and post-vaccination seroprotection to diphtheria and tetanus antigens were determined in the Immunology Analysis Set", 
                        "safety_issue": "No", 
                        "time_frame": "Day 0 (pre-vaccination) and day 28 post-vaccination", 
                        "title": "Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Pre-vaccination and Post-vaccination With ADACEL\u00ae", 
                        "type": "Other Pre-specified"
                    }, 
                    {
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received a single booster dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis vaccine (Tdap vaccine; ADACEL\u00ae) on Day 0.", 
                                "title": "Study Group"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "43"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "0.14", 
                                                        "@upper_limit": "0.35", 
                                                        "@value": "0.22"
                                                    }
                                                }, 
                                                "sub_title": "Diphtheria (Pre-vaccination)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "6.76", 
                                                        "@upper_limit": "10.88", 
                                                        "@value": "8.58"
                                                    }
                                                }, 
                                                "sub_title": "Diphtheria (Post-vaccination)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "0.33", 
                                                        "@upper_limit": "0.64", 
                                                        "@value": "0.46"
                                                    }
                                                }, 
                                                "sub_title": "Tetanus (Pre-vaccination)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "30.16", 
                                                        "@upper_limit": "47.38", 
                                                        "@value": "37.80"
                                                    }
                                                }, 
                                                "sub_title": "Tetanus (Post-vaccination)"
                                            }
                                        ]
                                    }, 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Geometric Mean", 
                                    "title": "Geometric Mean Concentrations With Respect to Diphtheria and Tetanus Antibodies Pre- and Post-vaccination With ADACEL\u00ae", 
                                    "units": "Titers"
                                }
                            ]
                        }, 
                        "population": "Pre and post vaccination geometric mean concentrations to Diphtheria and Tetanus antigens were determined in the Immunology Analysis Set", 
                        "safety_issue": "No", 
                        "time_frame": "Day 0 (pre-vaccination) and Day 28 post-vaccination", 
                        "title": "Geometric Mean Concentrations With Respect to Diphtheria and Tetanus Antibodies Pre- and Post-vaccination With ADACEL\u00ae", 
                        "type": "Other Pre-specified"
                    }, 
                    {
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received a single booster dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis vaccine (Tdap vaccine; ADACEL\u00ae) on Day 0.", 
                                "title": "Study Group"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "43"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "7.82", 
                                                        "@upper_limit": "19.05", 
                                                        "@value": "12.21"
                                                    }
                                                }, 
                                                "sub_title": "Pertussis toxoid (pre-vaccination)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "33.65", 
                                                        "@upper_limit": "65.42", 
                                                        "@value": "46.92"
                                                    }
                                                }, 
                                                "sub_title": "Pertussis toxoid (post-vaccination)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "23.47", 
                                                        "@upper_limit": "51.57", 
                                                        "@value": "34.79"
                                                    }
                                                }, 
                                                "sub_title": "Filamentous hemagglutinin (pre-vaccination)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "164.26", 
                                                        "@upper_limit": "253.36", 
                                                        "@value": "204.00"
                                                    }
                                                }, 
                                                "sub_title": "Filamentous hemagglutinin (post-vaccination)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "6.28", 
                                                        "@upper_limit": "18.03", 
                                                        "@value": "10.64"
                                                    }
                                                }, 
                                                "sub_title": "Pertactin (pre-vaccination)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "197.63", 
                                                        "@upper_limit": "376.62", 
                                                        "@value": "272.82"
                                                    }
                                                }, 
                                                "sub_title": "Pertactin (post-vaccination)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "5.42", 
                                                        "@upper_limit": "11.17", 
                                                        "@value": "7.78"
                                                    }
                                                }, 
                                                "sub_title": "Fimbriae types 2 and 3  (pre-vaccination)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "443.23", 
                                                        "@upper_limit": "1263.27", 
                                                        "@value": "748.28"
                                                    }
                                                }, 
                                                "sub_title": "Fimbriae types 2 and 3  (post-vaccination)"
                                            }
                                        ]
                                    }, 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Geometric Mean", 
                                    "title": "Geometric Mean Concentrations With Respect to Pertussis Antibodies Pre- and Post-vaccination With ADACEL\u00ae", 
                                    "units": "Titers"
                                }
                            ]
                        }, 
                        "population": "Pre and post vaccination geometric mean concentrations to pertussis antibodies were determined in the Immunology Analysis Set", 
                        "safety_issue": "No", 
                        "time_frame": "Day 0 (pre-vaccination) and Day 28 post-vaccination", 
                        "title": "Geometric Mean Concentrations With Respect to Pertussis Antibodies Pre- and Post-vaccination With ADACEL\u00ae", 
                        "type": "Other Pre-specified"
                    }, 
                    {
                        "description": "Booster responses were defined as: Pre-vaccination antibody concentrations less than the lower limit of quantitation (LLOQ) and a post-vaccination levels \u2265 4x LLOQ; or Pre-vaccination antibody concentrations \u2265 LLOQ but < 4x LLOQ, and a 4-fold rise (i.e., post-/pre-vaccination \u2265 4), or Pre-vaccination antibody concentrations \u2265 4x LLOQ and a 2-fold rise (i.e., post-/pre-vaccination \u2265 2)", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received a single booster dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis vaccine (Tdap vaccine; ADACEL\u00ae) on Day 0.", 
                                "title": "Study Group"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "43"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "93"
                                                    }
                                                }, 
                                                "sub_title": "Pertactin"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "98"
                                                    }
                                                }, 
                                                "sub_title": "Fimbriae Types 2 and 3"
                                            }
                                        ]
                                    }, 
                                    "description": "Booster responses were defined as: Pre-vaccination antibody concentrations less than the lower limit of quantitation (LLOQ) and a post-vaccination levels \u2265 4x LLOQ; or Pre-vaccination antibody concentrations \u2265 LLOQ but < 4x LLOQ, and a 4-fold rise (i.e., post-/pre-vaccination \u2265 4), or Pre-vaccination antibody concentrations \u2265 4x LLOQ and a 2-fold rise (i.e., post-/pre-vaccination \u2265 2)", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants With Booster Response to Pertussis Antigens, Pertactin and Fimbriae Following Vaccination With ADACEL\u00ae", 
                                    "units": "Percentage of Participants"
                                }
                            ]
                        }, 
                        "population": "Booster response to pertussis antigens were determined in the Immunology Analysis Set", 
                        "safety_issue": "No", 
                        "time_frame": "Day 28 post-vaccination", 
                        "title": "Percentage of Participants With Booster Response to Pertussis Antigens, Pertactin and Fimbriae Following Vaccination With ADACEL\u00ae", 
                        "type": "Other Pre-specified"
                    }, 
                    {
                        "description": "Solicited injection-site reactions: Pain, Redness, and Swelling. Grade 3: Pain, Significant, prevents daily activity; Redness and Swelling, >100 mm.\nSolicited systemic reactions: Fever (Temperature); Headache, Malaise, and Myalgia. Grade 3: Fever, \u2265 39\u00b0C; Headache, Malaise and Myalgia, Significant, prevents daily activity.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received a single booster dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis vaccine (Tdap vaccine; ADACEL\u00ae) on Day 0.", 
                                "title": "Study Group"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "43"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "37"
                                                    }
                                                }, 
                                                "sub_title": "Solicited injection site Pain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "Grade 3 solicited injection site Pain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "9"
                                                    }
                                                }, 
                                                "sub_title": "Solicited injection site Erythema"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "Grade 3 solicited injection site Erythema"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "12"
                                                    }
                                                }, 
                                                "sub_title": "Solicited injection site Swelling"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "Grade 3 solicited injection site Swelling"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "9"
                                                    }
                                                }, 
                                                "sub_title": "Fever"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "Grade 3 Fever"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "8"
                                                    }
                                                }, 
                                                "sub_title": "Headache"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "Grade 3 Headache"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "11"
                                                    }
                                                }, 
                                                "sub_title": "Malaise"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "Grade 3 Malaise"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "17"
                                                    }
                                                }, 
                                                "sub_title": "Myalgia"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "Grade 3 Myalgia"
                                            }
                                        ]
                                    }, 
                                    "description": "Solicited injection-site reactions: Pain, Redness, and Swelling. Grade 3: Pain, Significant, prevents daily activity; Redness and Swelling, >100 mm.\nSolicited systemic reactions: Fever (Temperature); Headache, Malaise, and Myalgia. Grade 3: Fever, \u2265 39\u00b0C; Headache, Malaise and Myalgia, Significant, prevents daily activity.", 
                                    "param": "Number", 
                                    "title": "Number of Participants Reporting Solicited Injection-site and Systemic Reactions Following Vaccination With ADACEL\u00ae", 
                                    "units": "Participants"
                                }
                            ]
                        }, 
                        "population": "Solicited injection site and systemic reactions were assessed in the Safety Analysis Set", 
                        "safety_issue": "No", 
                        "time_frame": "Day 0 up to Day 7 post-vaccination", 
                        "title": "Number of Participants Reporting Solicited Injection-site and Systemic Reactions Following Vaccination With ADACEL\u00ae", 
                        "type": "Other Pre-specified"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Participants received a single booster dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis vaccine (Tdap vaccine; ADACEL\u00ae) on Day 0.", 
                        "title": "Study Group"
                    }
                }, 
                "period_list": {
                    "period": {
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "43", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "43", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "0", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "pre_assignment_details": "A total of 43 participants that met all the inclusion criteria but none of the exclusion criteria were enrolled and vaccinated in the study.", 
                "recruitment_details": "The study participants were enrolled from 12 September through 14 October 2012 in 3 clinic centers in Japan."
            }, 
            "point_of_contact": {
                "email": "RegistryContactUs@sanofipasteur.com", 
                "name_or_title": "Medical Director", 
                "organization": "Sanofi Pasteur Inc."
            }, 
            "reported_events": {
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "Participants received a single booster dose of Tdap vaccine on Day 0.", 
                        "title": "Study Group"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "39", 
                                            "@subjects_at_risk": "43"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "assessment": "Systematic Assessment", 
                                            "counts": {
                                                "@events": "37", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "37", 
                                                "@subjects_at_risk": "43"
                                            }, 
                                            "sub_title": "Solicited injection site Pain"
                                        }, 
                                        {
                                            "assessment": "Systematic Assessment", 
                                            "counts": {
                                                "@events": "9", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "9", 
                                                "@subjects_at_risk": "43"
                                            }, 
                                            "sub_title": "Solicited injection site Erythema"
                                        }, 
                                        {
                                            "assessment": "Systematic Assessment", 
                                            "counts": {
                                                "@events": "12", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "12", 
                                                "@subjects_at_risk": "43"
                                            }, 
                                            "sub_title": "Solicited injection site Swelling"
                                        }, 
                                        {
                                            "assessment": "Systematic Assessment", 
                                            "counts": {
                                                "@events": "9", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "9", 
                                                "@subjects_at_risk": "43"
                                            }, 
                                            "sub_title": "Fever"
                                        }, 
                                        {
                                            "assessment": "Systematic Assessment", 
                                            "counts": {
                                                "@events": "11", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "11", 
                                                "@subjects_at_risk": "43"
                                            }, 
                                            "sub_title": "Malaise"
                                        }, 
                                        {
                                            "assessment": "Systematic Assessment", 
                                            "counts": {
                                                "@events": "17", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "17", 
                                                "@subjects_at_risk": "43"
                                            }, 
                                            "sub_title": "Myalgia"
                                        }
                                    ]
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@events": "9", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "7", 
                                            "@subjects_at_risk": "43"
                                        }, 
                                        "sub_title": "Nasopharyngitis"
                                    }
                                }, 
                                "title": "Infections and infestations"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@events": "8", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "8", 
                                            "@subjects_at_risk": "43"
                                        }, 
                                        "sub_title": "Headache"
                                    }
                                }, 
                                "title": "Nervous system disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA 15.1", 
                    "frequency_threshold": "5.00"
                }, 
                "time_frame": "Adverse event data were collected from Day 0 (post-vaccination) up to 1 month post-vaccination"
            }
        }, 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Pertussis", 
            "Tetanus", 
            "Diphtheria"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diphtheria", 
                "Whooping Cough", 
                "Tetanus", 
                "Tetany"
            ]
        }, 
        "detailed_description": {
            "textblock": "All participants will receive a single booster dose of Tdap vaccine (ADACEL\u00ae)  on Day 0 and\n      undergo immunogenicity assessment from blood samples provided prior to, and 28 days\n      post-vaccination. Tolerability and safety will be monitored up to 28 days post-vaccination."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged 11 or 12 years on the day of inclusion\n\n          -  Informed consent form and assent form signed and dated by the parent(s) / legal\n             representative and the subject respectively\n\n          -  Completed childhood vaccination against diphtheria, pertussis and tetanus (i.e,\n             received 4 doses of Japanese-produced tetanus toxoid, diphtheria toxoid and acellular\n             pertussis vaccine absorbed [DTaP vaccine]), confirmed by checking immunization\n             records and have not yet undergone additional adsorbed Diphtheria and Tetanus toxoid\n             (DT) vaccination\n\n          -  Able to attend all scheduled visits and to comply with all trial procedures\n\n          -  For female subjects, either pre-menarchal, or post-menarchal with a negative urine\n             pregnancy test.\n\n        Exclusion Criteria:\n\n          -  Any conditions or diseases which, in the opinion of the investigator\n\n          -  would pose a health risk to the subject\n\n          -  or might interfere with the ability to participate fully in the study\n\n          -  or might interfere with evaluation of the vaccine\n\n          -  or would otherwise make participation inappropriate according to the investigator's\n             clinical judgment\n\n          -  History of diphtheria, tetanus, pertussis, confirmed either clinically,\n             serologically, or microbiologically\n\n          -  Known systemic hypersensitivity to any of the vaccine components or history of a life\n             threatening reaction to a vaccine containing the same substances of the study vaccine\n\n          -  Vaccination in the last 5 years against tetanus, diphtheria, and/or pertussis\n\n          -  Known or suspected congenital immunodeficiency, or current / previous acquired\n             immunodeficiency, or current / previous receipt of immunosuppressive therapy such as\n             anti-cancer chemotherapy or radiation therapy, or current / previous (within the last\n             6 months) systemic corticosteroid therapy\n\n          -  Participation in another clinical trial investigating a vaccine, drug, medical\n             device, or medical procedure in the 4 weeks preceding the trial inclusion\n\n          -  Planned participation in another clinical trial during the present trial period\n\n          -  Receipt of blood or blood-derived products in the past 3 months, that might interfere\n             with assessment of the immune response\n\n          -  Receipt of any vaccine within the 4 weeks preceding the trial vaccination, except for\n             influenza vaccination, which may be received at least 2 weeks before the study\n             vaccine\n\n          -  Planned receipt of any vaccine during the trial period\n\n          -  Clinical or known serological evidence of systemic illness including Hepatitis B,\n             Hepatitis C and/or Human Immunodeficiency Virus (HIV) infection\n\n          -  At high risk for diphtheria, tetanus or pertussis infection during the trial\n\n          -  Known pregnancy, or a positive urine pregnancy test\n\n          -  Currently breastfeeding a child\n\n          -  Known thrombocytopenia, contraindicating intramuscular (IM) vaccination, or a history\n             of thrombocytopenia\n\n          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,\n             contraindicating IM vaccination\n\n          -  History of acute disseminated encephalomyelitis, encephalopathy, Guillain-Barr\u00e9\n             Syndrome (GBS), or autoimmune disease\n\n          -  Deprived of freedom by an administrative or court order, or in an emergency setting,\n             or hospitalized involuntarily\n\n          -  Current alcohol abuse or drug addiction that might interfere with the ability to\n             comply with trial procedures\n\n          -  Identified as an employee of an Investigator, a study center, a study-affiliated\n             vendor, or the Sponsor, with direct or indirect involvement in the proposed study or\n             other studies under the direction of that Investigator or study center; or identified\n             as a spouse or child (whether natural or adopted) of such an employee."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "12 Years", 
            "minimum_age": "11 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 17, 2012", 
        "firstreceived_results_date": "November 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01689324", 
            "org_study_id": "Td540", 
            "secondary_id": "U1111-1124-7671"
        }, 
        "intervention": {
            "arm_group_label": "Study Group", 
            "description": "0.5 mL, Intramuscular", 
            "intervention_name": "(ADACEL\u00ae): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis", 
            "intervention_type": "Biological", 
            "other_name": [
                "ADACEL\u00ae", 
                "Tdap Vaccine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pertussis", 
            "Tetanus", 
            "Diphtheria", 
            "Acellular pertussis", 
            "ADACEL\u00ae", 
            "Tdap vaccine"
        ], 
        "lastchanged_date": "February 19, 2014", 
        "link": [
            {
                "url": "http://www.sanofipasteur.com"
            }, 
            {
                "url": "http://www.sanofi.com"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aichi", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ibaraki", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagano", 
                        "country": "Japan"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Immunogenicity and Safety of the Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (SP306) as a Booster in Japanese Adolescents", 
        "other_outcome": [
            {
                "description": "Seroprotection was defined as the percentage of participants with antibody concentration of \u22650.1 IU/mL.", 
                "measure": "Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Pre-vaccination With ADACEL\u00ae", 
                "safety_issue": "No", 
                "time_frame": "Day 0 pre-vaccination"
            }, 
            {
                "description": "Seroprotection was defined as the percentage of participants with antibody concentration of \u22650.01 IU/mL.", 
                "measure": "Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Pre-vaccination and Post-vaccination With ADACEL\u00ae", 
                "safety_issue": "No", 
                "time_frame": "Day 0 (pre-vaccination) and day 28 post-vaccination"
            }, 
            {
                "description": "Seroprotection was defined as the percentage of participants with antibody concentration of \u22651.0 IU/mL.", 
                "measure": "Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Pre-vaccination and Post-vaccination With ADACEL\u00ae", 
                "safety_issue": "No", 
                "time_frame": "Day 0 (pre-vaccination) and day 28 post-vaccination"
            }, 
            {
                "measure": "Geometric Mean Concentrations With Respect to Diphtheria and Tetanus Antibodies Pre- and Post-vaccination With ADACEL\u00ae", 
                "safety_issue": "No", 
                "time_frame": "Day 0 (pre-vaccination) and Day 28 post-vaccination"
            }, 
            {
                "measure": "Geometric Mean Concentrations With Respect to Pertussis Antibodies Pre- and Post-vaccination With ADACEL\u00ae", 
                "safety_issue": "No", 
                "time_frame": "Day 0 (pre-vaccination) and Day 28 post-vaccination"
            }, 
            {
                "description": "Booster responses were defined as: Pre-vaccination antibody concentrations less than the lower limit of quantitation (LLOQ) and a post-vaccination levels \u2265 4x LLOQ; or Pre-vaccination antibody concentrations \u2265 LLOQ but < 4x LLOQ, and a 4-fold rise (i.e., post-/pre-vaccination \u2265 4), or Pre-vaccination antibody concentrations \u2265 4x LLOQ and a 2-fold rise (i.e., post-/pre-vaccination \u2265 2)", 
                "measure": "Percentage of Participants With Booster Response to Pertussis Antigens, Pertactin and Fimbriae Following Vaccination With ADACEL\u00ae", 
                "safety_issue": "No", 
                "time_frame": "Day 28 post-vaccination"
            }, 
            {
                "description": "Solicited injection-site reactions: Pain, Redness, and Swelling. Grade 3: Pain, Significant, prevents daily activity; Redness and Swelling, >100 mm.\nSolicited systemic reactions: Fever (Temperature); Headache, Malaise, and Myalgia. Grade 3: Fever, \u2265 39\u00b0C; Headache, Malaise and Myalgia, Significant, prevents daily activity.", 
                "measure": "Number of Participants Reporting Solicited Injection-site and Systemic Reactions Following Vaccination With ADACEL\u00ae", 
                "safety_issue": "No", 
                "time_frame": "Day 0 up to Day 7 post-vaccination"
            }
        ], 
        "overall_official": {
            "affiliation": "Sanofi Pasteur K.K", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Seroprotection was defined as the percentage of participants with antibody concentration of \u22650.1 IU/mL, post-vaccination.", 
                "measure": "Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Following Vaccination With ADACEL\u00ae", 
                "safety_issue": "No", 
                "time_frame": "Day 28 post-vaccination"
            }, 
            {
                "description": "Diphtheria booster response was defined as a \u2265 4-fold rise in pre- to post-vaccination antitoxin concentration in a subject with a pre-vaccination antitoxin concentration \u2264 2.56 IU/mL; or a \u2265 2-fold rise in a subject with a pre-vaccination antitoxin concentration > 2.56 IU/mL.\nTetanus booster response was defined as a \u2265 4-fold rise in pre- to post- vaccination antitoxin concentration in a subject with a pre-vaccination antitoxin concentration \u2264 2.7 IU/mL; or a \u2265 2-fold rise in a subject with a pre-vaccination antitoxin concentration > 2.7 IU/mL.", 
                "measure": "Percentage of Participants With Booster Response to Diphtheria and Tetanus Antigens Following Vaccination With ADACEL\u00ae", 
                "safety_issue": "No", 
                "time_frame": "Day 28 post-vaccination"
            }, 
            {
                "description": "Booster responses were defined as: Pre-vaccination antibody concentrations less than the lower limit of quantitation (LLOQ) and a post-vaccination levels \u2265 4x LLOQ; or Pre-vaccination antibody concentrations \u2265 LLOQ but < 4x LLOQ, and a 4-fold rise (i.e., post-/pre-vaccination \u2265 4), or Pre-vaccination antibody concentrations \u2265 4x LLOQ and a 2-fold rise (i.e., post-/pre-vaccination \u2265 2)", 
                "measure": "Percentage of Participants With Booster Response to Pertussis Antigens, Pertussis Toxoid and Filamentous Hemagglutinin Following Vaccination With ADACEL\u00ae", 
                "safety_issue": "No", 
                "time_frame": "Day 28 post-vaccination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01689324"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi Pasteur, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}